175 related articles for article (PubMed ID: 11952043)
1. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy.
Yokoyama N; Nagataki S; Uetani M; Ashizawa K; Eguchi K
Thyroid; 2002 Mar; 12(3):223-7. PubMed ID: 11952043
[TBL] [Abstract][Full Text] [Related]
2. [The value of DCE-MRI in assessing the course of thyroid associated ophthalmopathy].
Wu T; Tang DR; Wang F; Xia S; Sun FY
Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):430-435. PubMed ID: 28606264
[No Abstract] [Full Text] [Related]
3. Magnetic resonance imaging and ultrasound measurements of extraocular muscles in thyroid-associated ophthalmopathy at different stages of the disease.
Lennerstrand G; Tian S; Isberg B; Landau Högbeck I; Bolzani R; Tallstedt L; Schworm H
Acta Ophthalmol Scand; 2007 Mar; 85(2):192-201. PubMed ID: 17305734
[TBL] [Abstract][Full Text] [Related]
4. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance.
Villadolid MC; Yokoyama N; Izumi M; Nishikawa T; Kimura H; Ashizawa K; Kiriyama T; Uetani M; Nagataki S
J Clin Endocrinol Metab; 1995 Sep; 80(9):2830-3. PubMed ID: 7673432
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associated ophthalmopathy and proptosis.
Kvetny J; Puhakka KB; Røhl L
Acta Ophthalmol Scand; 2006 Jun; 84(3):419-23. PubMed ID: 16704711
[TBL] [Abstract][Full Text] [Related]
6. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy.
Hiromatsu Y; Kojima K; Ishisaka N; Tanaka K; Sato M; Nonaka K; Nishimura H; Nishida H
Thyroid; 1992; 2(4):299-305. PubMed ID: 1493371
[TBL] [Abstract][Full Text] [Related]
7. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia.
Nagy EV; Toth J; Kaldi I; Damjanovich J; Mezosi E; Lenkey A; Toth L; Szabo J; Karanyi Z; Leovey A
Eur J Endocrinol; 2000 Jun; 142(6):591-7. PubMed ID: 10832104
[TBL] [Abstract][Full Text] [Related]
8. Low signal intensities of MRI T1 mapping predict refractory diplopia in Graves' ophthalmopathy.
Matsuzawa K; Izawa S; Kato A; Fukaya K; Matsumoto K; Okura T; Miyazaki D; Kurosaki M; Fujii S; Taniguchi SI; Kato M; Yamamoto K
Clin Endocrinol (Oxf); 2020 Jun; 92(6):536-544. PubMed ID: 32090348
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of two-point Dixon T2-weighted imaging in thyroid-associated ophthalmopathy: comparison with conventional fat saturation imaging in fat suppression quality and staging performance.
Chen L; Hu H; Chen HH; Chen W; Wu Q; Wu FY; Xu XQ
Br J Radiol; 2021 Feb; 94(1118):20200884. PubMed ID: 33353397
[TBL] [Abstract][Full Text] [Related]
10. Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL.
Zhai L; Luo B; Wu H; Wang Q; Yuan G; Liu P; Ma Y; Zhao Y; Zhang J
Eur J Radiol; 2021 Sep; 142():109839. PubMed ID: 34252869
[TBL] [Abstract][Full Text] [Related]
11. Dixon MRI-based quantitative parameters of extraocular muscles, intraorbital fat, and lacrimal glands for staging thyroid-associated ophthalmopathy.
Pu XY; Chen L; Hu H; Wu Q; Jiang WH; Lu JL; Chen HH; Xu XQ; Wu FY
Insights Imaging; 2024 Jun; 15(1):136. PubMed ID: 38853188
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance evaluation of disease activity in Graves' ophthalmopathy: T2-time and signal intensity of extraocular muscles.
Majos A; Pajak M; Grzelak P; Stefańczyk L
Med Sci Monit; 2007 May; 13 Suppl 1():44-8. PubMed ID: 17507884
[TBL] [Abstract][Full Text] [Related]
13. Fractional anisotropy and diffusivity changes in thyroid-associated orbitopathy.
Han JS; Seo HS; Lee YH; Lee H; Suh SI; Jeong EK; Sapkota N; Kim KJ
Neuroradiology; 2016 Dec; 58(12):1189-1196. PubMed ID: 27844093
[TBL] [Abstract][Full Text] [Related]
14. ROLE OF MAGNETIC RESONANCE IMAGING IN THE ASSESSMENT OF ACTIVE THYROID-ASSOCIATED OPHTHALMOPATHY PATIENTS WITH LONG DISEASE DURATION.
Zhou M; Shen L; Jiao Q; Ye L; Zhou Y; Zhu W; Wang W; Wang S
Endocr Pract; 2019 Dec; 25(12):1268-1278. PubMed ID: 31412229
[No Abstract] [Full Text] [Related]
15. The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy.
Prummel MF; Gerding MN; Zonneveld FW; Wiersinga WM
Clin Endocrinol (Oxf); 2001 Feb; 54(2):205-9. PubMed ID: 11207635
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of rectus extraocular muscles using dynamic contrast-enhanced MR imaging in patients with Graves' ophthalmopathy for assessment of disease activity.
Jiang H; Wang Z; Xian J; Li J; Chen Q; Ai L
Acta Radiol; 2012 Feb; 53(1):87-94. PubMed ID: 22184678
[TBL] [Abstract][Full Text] [Related]
17. Extraocular muscle enlargement with tendon involvement in thyroid-associated orbitopathy.
Ben Simon GJ; Syed HM; Douglas R; McCann JD; Goldberg RA
Am J Ophthalmol; 2004 Jun; 137(6):1145-7. PubMed ID: 15183812
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg.
Politi LS; Godi C; Cammarata G; Ambrosi A; Iadanza A; Lanzi R; Falini A; Bianchi Marzoli S
Eur Radiol; 2014 May; 24(5):1118-26. PubMed ID: 24519110
[TBL] [Abstract][Full Text] [Related]
19. [Graves'ophthalmopathy: usefulness of T2 weighted muscle signal intensity].
Sillaire I; Ravel A; Dalens H; Garcier JM; Boyer L
J Radiol; 2003 Feb; 84(2 Pt 1):139-42. PubMed ID: 12717285
[TBL] [Abstract][Full Text] [Related]
20. [Magnetic resonance tomographic differentiation of ocular muscle changes in endocrine orbitopathy].
Hosten N; Cordes M; Sander B; Schörner W; Wenzel KW; Felix R
Rofo; 1990 Apr; 152(4):388-92. PubMed ID: 2160096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
